Navigation Links
Siemens Extends Tender Offer for Acquisition of Dade Behring
Date:9/5/2007

NEW YORK, Sept. 5 /PRNewswire-FirstCall/ -- Belfast Merger Co., a wholly owned subsidiary of Siemens Corporation, announced today that it has extended the expiration date for its cash tender offer for all outstanding shares of common stock of Dade Behring Holdings, Inc. (Nasdaq: DADE). The tender offer has been extended to 12:00 Midnight, New York City time, on Wednesday, September 26, 2007. The tender offer is being made pursuant to an Agreement and Plan of Merger, dated as of July 25, 2007, by and among Siemens, its subsidiary, Belfast Merger Co., and Dade Behring. Completion of the tender offer is conditioned on, among other things, receipt of regulatory approvals.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070904/SIEMENSLOGO )

As of 4:00 p.m., New York City time, on Wednesday, September 5, 2007, an aggregate of 39,128,122 shares of common stock of Dade Behring had been validly tendered and not withdrawn, representing 48.82 percent of the outstanding common stock of Dade Behring.

About Siemens

Siemens AG (NYSE: SI) (Berlin and Munich) is a global powerhouse in electrical engineering and electronics. The company has around 475,000 employees (incl. discontinued operations) working to develop and manufacture products, design and install complex systems and projects, and tailor a wide range of services for individual requirements. Siemens provides innovative technologies and comprehensive know-how to benefit customers in over 190 countries. Founded more than 160 years ago, the company focuses on the areas of Information and Communications, Automation and Control, Power, Transportation, Medical, and Lighting. In fiscal 2006 (ended September 30), Siemens had sales of euro87.3 billion and net income of euro3.033 billion, according to U.S. GAAP. Further information is available on the Internet at: http://www.siemens.com.

About Dade Behring

With 2006 revenue of more than US$1.7 billion, Dade Behring offers a wide range of products, systems and services designed to meet the day-to-day needs of clinical laboratories, delivering innovative solutions to customers and enhancing the quality of life for patients. Additional company information is available on the Internet at http://www.dadebehring.com.

This announcement is for informational purposes only and does not constitute an offer to purchase nor a solicitation of an offer to sell any securities. The Tender Offer Statement on Schedule TO, the Offer to Purchase and related materials filed by Siemens with the Securities and Exchange Commission ("SEC") contain important information and should be read carefully before any decision is made with respect to the tender offer. These materials are available at no charge on the SEC's web site (http://www.sec.gov) and requests for additional copies of such materials may be directed to Georgeson Inc., the Information Agent for the tender offer. The Information Agent can be reached at 17 State Street, 10th Floor, New York, New York 10004. Banks and brokers can call (212) 440-9800 and all others can call toll free at (888) 605-7608.


'/>"/>
SOURCE Siemens AG
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. India extends National TB Control Program
2. Irish Medicines Board Extends Paracetamol Recall To All Batches
3. Treatment Extends Survival in Mouse Model of Spinal Muscular Atrophy
4. Caloric Restriction in Non-obese People Extends Life Span
5. Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find
6. Nexavar Significantly Extends Survival of Liver Cancer Patients
7. Ranbaxy Labs Extends Roots in South Africa
8. Vitamin Extends Life in Yeast, Dartmouth Medical School Researchers Find
9. Singapore Extends Smoking Ban to Pubs, Nightclubs
10. CCEA Extends National TB Control Project for Five Years
11. FDA Extends GRAS Approval Listex to All Food Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... NY (PRWEB) , ... December 09, 2016 , ... ... and Drug Dependence, Inc. (NCADD) is recommending the film Whispering Spirits ... and the District of Columbia as an education tool in the war against teen ...
(Date:12/9/2016)... ... December 09, 2016 , ... ... Pierre Hotel in New York, NY, on December 3rd, to benefit Holy Name ... attended the annual event, which raised over $1 million - the largest event ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Quality Insights beginning January 1, 2017. The name change aligns the entire ... measuring and improving health care quality. , “We are very proud of the ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... pleased to announce that “Natural Language Processing–Enabled and Conventional Data Capture Methods for ... JMIR Medical Informatics . , Results of the comparative usability study demonstrate ...
(Date:12/8/2016)... ... ... With the increasing demand for dental implants, the National Association of Dental ... dentists and patients about the safety issues related to dental restorations. According to the ... is projected to reach $6.4 billion in 2018 with more than 30 million Americans ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... DIEGO , Dec. 9, 2016 aTyr Pharma, Inc. ... discovery and development of Physiocrine-based therapeutics to address severe, rare diseases, ... at the upcoming BMO Prescriptions for Success Healthcare Conference at the ... on Wednesday, December 14, 2016, at 4:20 p.m. ET. ... ...
(Date:12/9/2016)... , Dec. 9, 2016  Axovant Sciences Ltd. ... biopharmaceutical company focused on the treatment of dementia, ... from a Phase 2b trial evaluating treatment with ... compared with donepezil plus placebo in people with ... addition of intepirdine to treatment was associated with ...
(Date:12/8/2016)... , Dec. 8, 2016 Australia Glaucoma ... GlobalData,s new report, "Australia Glaucoma Surgery Devices ... on the Australia Glaucoma Surgery Devices market. The ... volume (in units) and average prices (USD) within ... report also provides company shares and distribution shares ...
Breaking Medicine Technology: